Search

Your search keyword '"Daniel P. Krowchuk"' showing total 190 results
Start Over Author "Daniel P. Krowchuk"
190 results on '"Daniel P. Krowchuk"'

3. Pediatric Dermatology : A Quick Reference Guide

Author

Anthony J. Mancini, Daniel P. Krowchuk, Anthony J. Mancini, and Daniel P. Krowchuk

Subjects
Children, Infants, Pediatric dermatology--Handbooks, manuals, etc, Skin--Diseases
Abstract

Significantly updated and revised, this best-selling quick reference provides practical and concise guidance on the recognition and treatment of more than 100 pediatric and adolescent skin conditions. Includes more than 300 full color images that aid in accurate visual diagnosis. Coverage spans everything from dermatitis and acne to infections, pigmentation disorders, hair disorders, neonatal and infant conditions, drug eruptions, and much more.Key FeaturesNine new chaptersCercarial DermatitisPityriasis Rubra Pilaris (PRP)PilomatricomaSpitz NevusEctodermal DysplasiaSubcutaneous Fat NecrosisStevens-Johnson Syndrome (SJS) and Mycoplasma pneumoniae-Induced Rash and MucositisConfluent and Reticulated Papillomatosis (CARP)Hyperhidrosis35+ new color images to aid in accurate visual diagnosis Must-have information on each condition is presented in the precise sequence in which you need it in the clinical setting: Etiology/epidemiologySymptoms and signsHow to make the diagnosisTreatmentPrognosisReferral considerationsResources for familiesContent highlights: Approach to the patient with a rashDiagnostic TechniquesTherapeuticsDermatitisAcneLocalized Viral InfectionsSystemic Viral InfectionsLocalized Bacterial InfectionsSystemic Bacterial, Rickettsial, or Spirochetal Infections with Skin ManifestationsFungal and Yeast InfectionsInfestations & BitesPapulosquamous DiseasesVascular LesionsHypopigmentationHyperpigmentationLumps and BumpsBullous DiseasesGenodermatosesHair DisordersSkin Disorders in Neonates/InfantsAcute Drug/Toxic ReactionsCutaneous Manifestations of Rheumatologic DiseasesNutritional DermatosesOther Disorders

Published
2021

10. Clinical Practice Guideline for the Management of Infantile Hemangiomas

Author

Francine Blei, David H. Darrow, Daniel P. Krowchuk, Stuart T. Weinberg, Cynthia N. Baker, Deborah Sandrock, Amy Hodak, Peter C. Frommelt, Anthony J. Mancini, Arin K. Greene, Ilona J. Frieden, Aparna Annam, Janice L. Pelletier, Brian M. Pate, and Mary Anne Whelan

Subjects
Pediatrics, medicine.medical_specialty, Skin Neoplasms, business.industry, Laser treatment, Specialty, Disease Management, Infant, Guideline, Disfigurement, medicine.disease, Combined Modality Therapy, Benign tumor, Clinical Practice, 03 medical and health sciences, 0302 clinical medicine, 030225 pediatrics, Practice Guidelines as Topic, Pediatrics, Perinatology and Child Health, medicine, Humans, Active treatment, Hemangioma, business, Airway
Abstract

Infantile hemangiomas (IHs) occur in as many as 5% of infants, making them the most common benign tumor of infancy. Most IHs are small, innocuous, self-resolving, and require no treatment. However, because of their size or location, a significant minority of IHs are potentially problematic. These include IHs that may cause permanent scarring and disfigurement (eg, facial IHs), hepatic or airway IHs, and IHs with the potential for functional impairment (eg, periorbital IHs), ulceration (that may cause pain or scarring), and associated underlying abnormalities (eg, intracranial and aortic arch vascular abnormalities accompanying a large facial IH). This clinical practice guideline for the management of IHs emphasizes several key concepts. It defines those IHs that are potentially higher risk and should prompt concern, and emphasizes increased vigilance, consideration of active treatment and, when appropriate, specialty consultation. It discusses the specific growth characteristics of IHs, that is, that the most rapid and significant growth occurs between 1 and 3 months of age and that growth is completed by 5 months of age in most cases. Because many IHs leave behind permanent skin changes, there is a window of opportunity to treat higher-risk IHs and optimize outcomes. Early intervention and/or referral (ideally by 1 month of age) is recommended for infants who have potentially problematic IHs. When systemic treatment is indicated, propranolol is the drug of choice at a dose of 2 to 3 mg/kg per day. Treatment typically is continued for at least 6 months and often is maintained until 12 months of age (occasionally longer). Topical timolol may be used to treat select small, thin, superficial IHs. Surgery and/or laser treatment are most useful for the treatment of residual skin changes after involution and, less commonly, may be considered earlier to treat some IHs.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results